CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cell product. This episode also covers studies of trispecific CAR T-cells targeting CD19, CD20, and CD22. Stay tuned to learn more about these promising approaches from experts Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain. The post Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms appeared first on VJHemOnc.

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Selina Luger, MD, FRCPC, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, Harry Erba, MD, PhD, Duke University, Durham, NC, Fabio Guolo, MD, University of Genoa, Genoa, Italy, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL. The experts discuss key trials in this space, including venetoclax combined with intensive induction chemotherapy, a Phase II study comparing midostaurin with gilteritinib in FLT3-mutated AML (NCT03836209), and the combination of ziftomenib with intensive chemotherapy. They also examine the role of CPX-351 in induction therapy and its potential combination with gemtuzumab ozogamicin. The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients. In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, and David Lewis, MD, Plymouth University, Plymouth, UK. The experts cover a variety of topics, exploring the role of BTK inhibitors in R/R MCL, promising combinations being explored, and strategies to overcome resistance. The post Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance appeared first on VJHemOnc.

In this enlightening discussion, Joseph Mikhael, a myeloma expert from TGen and the International Myeloma Foundation, tackles the pressing issues in myeloma treatment. He highlights breakthroughs in managing smoldering myeloma and the unique challenges faced by frail and elderly patients. The conversation also dives into innovative therapies for triple-class refractory disease, and the critical examination of racial disparities in myeloma care. Mikhael’s insights showcase the need for improved access and personalized treatment approaches.

Discover groundbreaking updates on CAR T-cell therapy for acute lymphoblastic leukemia. Experts discuss the pivotal CART19-BE-02 trial results and the FDA approval of obecabtagene autoleucel for relapsed B-ALL. Insights into the safety and efficacy of brexucabtagene autoleucel for older patients highlight promising outcomes. Innovative trials, including a phase two study of WU-CAR and tri-specific CAR T-cells, showcase strong safety profiles and exciting potential for future treatments in hematological malignancies.

In this insightful discussion, Vaishali Sanchorawala, a leading expert in amyloidosis from Boston University, and Ashutosh Wechalekar, a prominent hematologist from University College London, delve into the cutting-edge findings presented at the recent ASH meeting. They highlight breakthrough results from the ANDROMEDA trial, emphasizing the effectiveness of daratumumab VCD for AL amyloidosis treatment. The duo also explores advancements in risk stratification and the promising role of measurable residual disease and CAR T-cell therapy in enhancing patient care.

Dr. Rabi Hanna from Cleveland Clinic shares insights on innovative treatments for severe sickle cell disease. He presents updated results from the RUBY trial, highlighting the potential of reni-cel as a groundbreaking gene therapy. The conversation also touches on the promising outcomes of the HIBISCUS trial for Etavopivat, showing significant improvements in patient quality of life. Furthermore, advancements in thalassemia treatments are discussed, focusing on reduced transfusion needs from the ENERGIZE-T study.

Discover groundbreaking insights on treating smoldering myeloma, with a focus on the AQUILA study showcasing daratumumab's survival benefits. Delve into the advancements in bispecific antibodies, revealing new treatment options for relapsed myeloma. The experts forecast exciting developments for 2025, emphasizing the role of measurable residual disease (MRD) in patient outcomes. Additionally, explore the evolving definition of high-risk myeloma and the emergence of innovative therapies for these challenging cases.

Dive into the latest advancements in acute myeloid leukemia treatment showcased from the ASH Annual Meeting. Experts discuss innovative frontline therapies and the promising role of menin inhibitors in relapsed cases. Learn about the safety profiles and dosing strategies of Blexmenib, along with the efficacy of triplet therapies, particularly for FLT3-ITD+ patients. The conversation emphasizes the importance of continuous research to refine treatment options and improve outcomes for various patient demographics.

Claire Harrison, MD, a renowned expert from Guy’s and St Thomas’ NHS Foundation Trust, shares insights on cutting-edge developments in myelofibrosis therapies post-ASH. She discusses the promising RESTORE trial for l-ritrecept and highlights innovative combinations like regulatory T-cells with ruxolitinib. Exciting updates on the SANRECO trial for polycythemia vera show a reduction in phlebotomy needs, while new agents such as Nuvisertib promise significant patient outcomes. The potential of groundbreaking treatments is transforming the landscape of myelofibrosis management.